We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
-19.74%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$275M
AUM Growth
-$16.9M
(-5.8%)
Cap. Flow
+$82.8M
Cap. Flow
% of AUM
30.18%
Top 10 Holdings %
Top 10 Hldgs %
36.4%
Holding
93
New
30
Increased
20
Reduced
14
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cencora
COR
|
+$11.5M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$11M |
| 3 |
CVS Health
CVS
|
+$10.8M |
| 4 |
Medtronic
MDT
|
+$8.96M |
| 5 |
Cardinal Health
CAH
|
+$7.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$14.6M |
| 2 |
AET
Aetna Inc
AET
|
+$12.3M |
| 3 |
Kura Oncology
KURA
|
+$7.72M |
| 4 |
Biogen
BIIB
|
+$6.82M |
| 5 |
Elevance Health
ELV
|
+$6.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.89% |
| 2 | Miscellaneous | 5.11% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Medtronic
MDT
$117B
| $11.9M | 4.34% |
131,115
+95,919
| +273% | +$8.96M |
|
2
Sanofi
SNY
$107B
| $11.7M | 4.24% |
268,388
+2,000
| +0.8% | +$88.2K |
|
3
Alnylam Pharmaceuticals
ALNY
$31.7B
| $11.3M | 4.11% |
154,637
+50,461
| +48% | +$3.88M |
|
|
4
Cencora
COR
$61.5B
| $9.96M | 3.63% |
+133,934
| New | +$11.5M |
|
5
Cigna
CI
$73.7B
| $9.92M | 3.61% |
52,216
-15,233
| -23% | -$3.18M |
|
6
PUT
Amgen
AMGN
$234B
| $9.73M | 3.55% |
50,000
| – | – |
|
|
7
CVS Health
CVS
$119B
| $9.49M | 3.46% |
+144,777
| New | +$10.8M |
|
|
8
Cardinal Health
CAH
$54.6B
| $9.32M | 3.4% |
209,009
+147,005
| +237% | +$7.66M |
|
9
HCA Healthcare
HCA
$90.5B
| $8.47M | 3.08% |
68,039
-15,783
| -19% | -$2.12M |
|
|
GWPH
10
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $8.2M | 2.99% |
+84,186
| New | +$11M |
|
|
NVO
11
Novo Nordisk
NVO
$202B
| $6.79M | 2.47% |
+294,756
| New | +$6.55M |
|
|
CELG
12
DELISTED
Celgene Corp
CELG
| $6.56M | 2.39% |
+102,390
| New | +$7.56M |
|
|
LITS
13
Lite Strategy Inc
LITS
$33.4M
| $6.27M | 2.28% |
118,692
+3,510
| +3% | +$216K |
|
14
Gilead Sciences
GILD
$181B
| $6.04M | 2.2% |
+96,480
| New | +$6.74M |
|
|
UROV
15
DELISTED
Urovant Sciences Ltd.
UROV
| $5.32M | 1.94% |
807,860
+216,406
| +37% | +$1.97M |
|
16
McKesson
MCK
$104B
| $5.14M | 1.87% |
+46,530
| New | +$5.8M |
|
17
Viatris
VTRS
$18.8B
| $5.13M | 1.87% |
+187,175
| New | +$6.06M |
|
|
PINC
18
DELISTED
Premier
PINC
| $5.02M | 1.83% |
134,412
-10,000
| -7% | -$413K |
|
19
Rigel Pharmaceuticals
RIGL
$868M
| $5.01M | 1.83% |
218,055
+33,705
| +18% | +$951K |
|
20
Molina Healthcare
MOH
$10.4B
| $4.98M | 1.81% |
+42,869
| New | +$5.62M |
|
21
Neurocrine Biosciences
NBIX
$15.7B
| $4.93M | 1.79% |
+69,000
| New | +$6.61M |
|
22
Viking Therapeutics
VKTX
$3.75B
| $4.87M | 1.78% |
637,046
+423,794
| +199% | +$5.07M |
|
23
Bionano Genomics
BNGO
$13.8M
| $4.85M | 1.77% |
2,394
-7
| -0.3% | -$27.9K |
|
|
DRNA
24
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $4.74M | 1.73% |
+443,409
| New | +$5.83M |
|
25
Humana
HUM
$46.3B
| $4.67M | 1.7% |
16,317
-3,737
| -19% | -$1.18M |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, Sio Capital Management held 93 positions worth $275M, down 5.8% from $291M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Sio Capital Management deployed $82.8M of net new capital in Q4 2018, opening 30 new positions and adding to 20 existing holdings. Its largest new stake was Cencora: 133,934 shares worth $9.96M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Kura Oncology, an estimated $7.72M trimmed.
- Sio Capital Management's largest Q4 2018 buy was Cencora: 133,934 shares worth $9.96M.
- Sio Capital Management added most to Medtronic in Q4 2018, an estimated $8.96M increase.
- Sio Capital Management's biggest Q4 2018 reduction was Kura Oncology, cutting an estimated $7.72M.
- Sio Capital Management fully exited GSK in Q4 2018, selling an estimated $14.6M.
- Sio Capital Management's ten largest holdings make up 36% of its $275M portfolio in Q4 2018.
- Sio Capital Management opened 30 new positions and closed 25 in Q4 2018.
- Sio Capital Management's portfolio value fell 5.8% quarter-over-quarter to $275M.
Based on Sio Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.